Most read dermatitis articles of 2022
The FDA’s approval of Rinvoq, a selective Janus kinase (JAK) inhibitor, was Healio’s most read dermatitis story in 2022, with multiple articles about Cibinqo and roflumilast following close behind.
Here are Healio’s top 10 dermatitis stories of 2022:
FDA approves Rinvoq for atopic dermatitis
Kicking off the year, the FDA approved Rinvoq, a selective JAK inhibitor, for the treatment of moderate to severe AD among patients aged 12 years and older. The approval was supported by safety and efficacy results across three AD studies. Read more.
Cibinqo effective option for AD regardless of previous Dupixent use
Cibinqo safely and effectively treated moderate to severe AD among patients regardless of any previous treatment with Dupixent, according to data published in the Journal of the American Academy of Dermatology in April. Read more.
FDA approves Cibinqo for moderate to severe AD
In January, the FDA approved Pfizer’s Cibinqo, an oral, once-daily JAK inhibitor, for the treatment of patients with moderate to severe AD. The approval followed the success of three phase 3 trials that demonstrated the drug’s safety profile and effectiveness in improving disease severity and itch among 1,600 patients. Read more.
Opzelura cream well-tolerated, effective for treating AD
Data published in the American Journal of Clinical Dermatology in the spring showed that Opzelura cream, a potent, selective inhibitor of JAK1 and JAK2, was a well-tolerated and effective topical treatment for patients with AD. Read more.
FDA approves Dupixent for AD in young children
In June, the FDA extended the approval of Dupixent to include children aged 6 months to 5 years with moderate to severe AD. The approval was based on phase 3 data that found various doses of Dupixent to be effective in clearing or almost clearing skin in 28% of patients. Read more.
Roflumilast efficacious in reducing seborrheic dermatitis itch
At the American Academy of Dermatology meeting in March, researchers presented their findings on roflumilast foam 0.3%. The drug was found to improve itch and quality of life in seborrheic dermatitis patients in an 8-week, phase 2 trial. Read more.
Lebrikizumab maintains AD skin clearance for 1 year
The spring and summer proved busy in the dermatology world with another June article making the top 10 list. According to results from two phase 3 trials announced by Eli Lilly and Company, lebrikizumab monotherapy was efficacious in improving AD in 80% of patients at 1 year. Read more.
Roflumilast foam efficacy in seborrheic dermatitis spans race, ethnicity
At the European Academy of Dermatology and Venereology Congress in September, researchers again presented positive results for roflumilast foam. Roflumilast foam was well tolerated and efficacious in seborrheic dermatitis patients with all skin types, according to the presentation, with 73.8% of roflumilast-treated patients achieving IGA success. Read more.
Roflumilast foam shows positive topline results in seborrheic dermatitis
Once again, roflumilast foam showed positive results in the seborrheic dermatitis community in a phase 3 trial this past June, according to a press release from Arcutis Biotherapeutics. Patients in this trial exhibited statistically significant improvements in disease severity with 50% achieving IGA scores of clear by week 8. Read more.
Photoaggravated AD warrants more attention, testing
Published in July, a study showed that photoaggravated AD, which affects people of varied ages and with different skin phototypes, has a significant impact on quality of life. The authors stated that “photoaggravated atopic dermatitis (PAD) is a poorly understood subtype of AD that is worsened or provoked by exposure to UV radiation.” The authors called for improved treatment for this condition. Read more.